Therapeutic treatment of bleomycin‐challenged rats with either the ALK‐5 inhibitor SB‐525334 or Imatinib attenuated the increases in RV hypertrophy and RV pressure associated with pulmonary fibrosis. Here, TGFBR1 is linked to pulmonary fibrosis.